Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(5 sites)

Italy

Fondazione IRCCS San Gerardo Dei Tintori, Monza, Monza

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Roma

Azienda Sanitaria Locale Br, Brindisi

European Institute of Oncology, Milan